Syros Pharmaceuticals Inc. (SYRS) Company Projected Revenue

Syros - graphic logo of issuer SYRS

Syros Pharmaceuticals management is skillfully developing gene technologies to combat cancer, leveraging a product cycle that remains independent of macroeconomic trends. The company's future trading volume demonstrates the result of this strategy, with the current value recorded at 0.00. However, geopolitical risks that limit international testing and patent protection continue to impact the final outcome.

Company Future Sales Volume: Syros Pharmaceuticals, Inc (SYRS) for 07/04/2022 - 03/29/2025

Metric breakdowns and analytics for Syros (SYRS)

- stock quotes and analyst forecast:
Analysis of all company metrics:syros.com SYRS
Brand item of Syros Pharmaceuticals Inc.

It is essential for investors to protect capital from market volatility during periods of uncertainty. The current restructuring of the R&D pipeline at Syros Pharmaceuticals (SYRS) and strict resource austerity underscore the critical importance of future revenues. This metric assesses the resilience of expected cash flows, filtering out random market fluctuations. By analyzing the company's projected sales levels, one can determine the commercialization potential of the single remaining molecule. This allows for an assessment of the risk of asset freezing in the event of a potential cooling of demand.

Analysis of competing companies

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|PHIO - Company Projected Revenue|Company Future Revenue MBIO (mustangbio.com)|RNAZ: Projected Sales Volume|Company Revenue Forecast BNGO|APDN (Applied DNA Corp) - Projected Sales Volume|BLUE: Company Future Revenue|Company Projected Revenue ImmunoPrecise (IPA)|OMGA - Company Expected Sales Volume|Company Projected Revenue Singular Genomics OMIC|Company Future Revenue RGLS|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume